Feed BHC
BH

Bausch Health

BHC · NYSE

$5.64 -0.62% (-$0.04)
1M -15.57%
Market Cap $2.11B
P/E Ratio -
Div. Yield -
ROE -

Bulios Fair Price

$7.15

26.9% upside

Current Price

$5.64

Undervalued Fair Value Overvalued

According to Bulios Fair Price, BHC is currently undervalued relative to its market price. How does it work?

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Piotroski F-Score Moderate
6/9
Valuation
89 /100
Cheap
P/S 0.19x
P/FCF 1.51x
EV/EBITDA 10.29x
Growth
61 /100
Stable
Rev. growth 8.74%
FCF growth N/A
Book val. growth N/A
Profitability
73 /100
Strong
Net margin 10.12%
Op. margin 25.44%
FCF margin 12.83%
Quality
64 /100
Average
ROA 4.43%
Asset turnover 0.44x
ROIC 19.51%
Debt
17 /100
High
Int. coverage 0.54x
Net debt/EBITDA 9.26x
Current ratio 1.44x
Stability
44 /100
Moderate
Rev. volatility 1.08%
EPS volatility 297.06%
Profitable years 1

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about BHC
Online

About the company

Bausch Health Companies Inc. is a Canadian pharmaceutical company focused on the development and manufacturing of medicines and healthcare products. Originally founded in 1959 as Valeant Pharmaceuticals, the company rebranded as Bausch Health in 2018, shifting its focus to products in ophthalmology, dermatology, dental care, and cardiovascular medicine. Bausch Health specializes in prescription drugs, over-the-counter products, and innovative medical devices, and is known for its strong portfolio in ophthalmology and medical technologies.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

CEO

Thomas J. Appio

Employees

20,300

Headquarters

Laval

Upcoming events

28 OCT

Earnings

Upcoming earnings report

36d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.